Artiva (ARTV) 10% Owner RA Capital Management Buys Shares

What Happened
RA Capital Management, L.P. (a reported 10% holder) acquired a total of 45,768 shares of Artiva Biotherapeutics, Inc. (ARTV) in two purchases. On 2026-07-29 it bought 20,824 shares at a weighted average price of $9.99 (≈ $208,032) and on 2026-07-31 it bought 24,944 shares at a weighted average price of $9.93 (≈ $247,694). Combined consideration is approximately $455,726. These were purchases (accumulative activity) reported on a Form 4.

Key Details

• Transaction type: P = Purchase (open market or private purchase as reported).
• Dates & reported weighted-average prices: 7/29/2026 — 20,824 sh @ $9.99 (F1: per-share prices ranged $9.84–$10.00); 7/31/2026 — 24,944 sh @ $9.93 (F4: per-share prices ranged $9.82–$9.97). The filer can provide per-price breakdown on request.
• Total shares purchased: 45,768; total value ≈ $455,726.
• Shares owned after transaction: Not disclosed in the excerpt provided.
• Filing: Form 4 filed 2026-07-31 for transactions through 2026-07-29 — appears timely (Form 4 is generally due within two business days).
• Notable footnotes: F2 explains RA Capital is the adviser for multiple funds/accounts and that the Adviser and related parties disclaim beneficial ownership except to the extent of pecuniary interest. F3/F5/F6/F7 indicate some holdings are held directly by specific funds/accounts.
• Other remark: Laura Stoppel, a Partner of the Adviser, serves on Artiva’s board of directors.

Context
This is institutional buying by a reported 10% owner (an investment manager and its funds), not a typical executive/director personal trade. Institutional purchases can indicate fund-level accumulation but do not necessarily reflect an individual insider's personal view. The filing includes weighted-average price ranges and organizational disclaimers about beneficial ownership — standard for investment-manager filings.